# A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

> **NCT04812548** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** sabatolimab
- **DRUG:** azacitidine
- **DRUG:** venetoclax

## Key facts

- **NCT ID:** NCT04812548
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-31
- **Primary completion:** 2023-05-08
- **Final completion:** 2023-05-08
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Study was stopped following a strategic decision from the Sponsor. It was not based on any safety findings or safety concerns with sabatolimab.
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04812548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04812548, "A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04812548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*